Premium
Metrifonate: Overview of Safety and Efficacy
Author(s) -
Cummings Jeffrey L.
Publication year - 1998
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1998.tb03877.x
Subject(s) - nausea , cholinesterase , placebo , medicine , cognition , acetylcholine , pharmacology , adverse effect , disease , psychiatry , alternative medicine , pathology
Metrifonate is a cholinesterase inhibitor with a long‐lasting inhibition that raises brain acetylcholine levels. It is well‐absorbed and has limited binding to serum proteins. In preliminary studies of its utility in the treatment of Alzheimer disease's (AD), it led to improvements of cognition or reduced the rate of decline of cognition compared with placebo. It also benefited the global function of these patients. Side effects include nausea, cramping, and diarrhea. Metrifonate has promise as a well‐tolerated treatment of the symptoms of AD.